Aurore life sciences to merge with Solara active pharma sciences limited in an all-stock transaction and the shareholders of Aurore will have 27% ownership in the merged entity.
Merged entity will have 8 manufacturing sites, 3 R & D center, 100+ commercial products, 110+ DMFs, 3200 + employees & 310 + scientists.
Post the deal, the company shall operate as Solara. Estimated deal closure date is March 2022.
